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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Abstract: In order to prevent cardiovascular events, it is essential to effectively manage overall risk 
of cardiovascular disease. However, despite guideline recommendations to this effect, current man-
agement of the major, modiﬁ  able cardiovascular risk factors such as hypertension and dyslipidemia 
is disconnected and patient adherence to therapy is poor. This is particularly important for patients 
with multiple cardiovascular risk factors, who are often prescribed multiple medications. The JEWEL 
study program investigated the use of single-pill amlodipine/atorvastatin as a strategy to improve 
management of these patients. The JEWEL program consisted of two 16-week, international, open-
label, multicenter, titration-to-goal studies in patients with hypertension and dyslipidemia. The two 
studies differed based on country of enrollment and certain tertiary endpoints, but the overall designs 
were very similar. Patients were enrolled from 255 centers across Canada and 13 European countries. 
The study was designed to assess the efﬁ  cacy, safety, and utility of amlodipine/atorvastatin single-
pill therapy in a real-world setting. Patients were initiated at a dose of amlodipine 5 mg/atorvastatin 
10 mg, unless previously treated, and were uptitrated as necessary. The primary efﬁ  cacy parameter 
was the percentage of patients, at different levels of cardiovascular risk, achieving country-speciﬁ  c 
guideline-recommended target levels for blood pressure and lipids. A secondary analysis of efﬁ  cacy 
measured attainment of the same single goal for blood pressure across all study participants (JEWEL 
I and II) and the same single goal for LDL-C across all study participants (JEWEL I and II). The 
program utilized a newly developed questionnaire to gain better understanding of participants’ 
beliefs and behaviors towards medical treatment of their multiple risk factors. Approximately 2850 
patients were enrolled in the program, which was completed in August 2005. The JEWEL program  
assessed the effectiveness of a single pill (amlodipine/atorvastatin) in targeting the two principal risk 
factors for cardiovascular disease simultaneously to achieve nationally applicable treatment targets 
in a routine clinical practice setting.
Keywords: amlodipine, atorvastatin, risk factors, hypertension, dyslipidemia, cardiovascular 
disease
Background
Cardiovascular disease (CVD) is the world’s most important cause of death, driven by the 
high rates of coronary heart disease and stroke in ﬁ  ve out of the six World Health Organiza-
tion regions (WHO 2002). Since CVD also drives high healthcare costs in those surviving 
events such as stroke and heart failure, better strategies to facilitate the prevention and 
treatment of cardiovascular disease have become priorities for most healthcare systems.
Cardiovascular risk factors
The major modiﬁ  able risk factors for cardiovascular disease are well documented, with the 
principal three being: abnormal plasma lipid levels (high levels of low-density lipoprotein Vascular Health and Risk Management 2006:2(4) 465–475
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year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
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cholesterol [LDL-C] and triglycerides, and low levels of 
high-density lipoprotein cholesterol [HDL-C]) (Anderson 
et al 1987; Verschuren et al 1995); hypertension (MacMahon 
et al 1990); and smoking (Multiple Risk Factor Intervention 
Trial Group 1982; Greenland et al 2003). Several large epi-
demiological surveys have shown that 80%–90% of patients 
with coronary heart disease have at least one of these three 
risk factors (O’Meara et al 2004), and that each risk factor has 
a continuous, severity-dependent impact on risk for coronary 
heart disease (Neaton et al 1992; NCEP 2001; Thomas et al 
2002). Additional cardiovascular risk factors include age ( 55 
years), male gender, presence of other vascular disease (history 
of stroke or peripheral arterial disease), diabetes mellitus 
(Haffner et al 1998), proteinuria, left ventricular hypertrophy, 
and family history of premature coronary heart disease.
Cardiovascular risk factors rarely occur in isolation and 
many subjects present with a combination of conditions that 
contribute to their total risk of cardiovascular disease (Khot 
et al 2003; Jackson et al 2005). According to an analysis based 
on Framingham data, 78% of hypertensive men and 82% of 
hypertensive women have at least one other cardiovascular 
risk factor (Kannel 2000). The principal European CVD risk 
study, the WHO MONItoring of trends and determinants in 
CArdiovascular disease (MONICA) project, indicated that 
approximately 35% of Western Europeans have both condi-
tions (Tunstall-Pedoe et al 2004). Similar studies of CVD risk 
factors in France showed that 84% of hypertensive men and 
77% of  hypertensive women have at least one other cardiovas-
cular risk factor (Asmar et al 2001), and that 20% of adults in 
the United Kingdom (UK) have concomitant hypertension and 
dyslipidemia (representing 9.2 million people) (Williams et al 
2004). These ﬁ  ndings are of major clinical signiﬁ  cance, since 
even borderline elevations in both blood pressure (BP) and 
serum cholesterol can dramatically increase the prevalence of 
cardiovascular disease and the risk of coronary heart disease.
Prevention guidelines from the US (NCEP 2001; 
Chobanian et al 2003), Canada (Khan et al 2004), and Europe 
(Guidelines Committee 2003; Williams et al 2004) highlight 
the need for an overall approach towards assessment of a 
patient’s risk of morbidity and mortality from cardiovas-
cular disease. These guidelines recommend assessment of 
total cardiovascular risk and encourage individually tailored 
therapy to address all risk factors.
Managing cardiovascular risk and
current practice
Encouraging lifestyle modiﬁ  cations should be the corner-
stone of all treatment programs (NCEP 2001; Williams 
et al 2004); however lifestyle modiﬁ  cations are not always 
successful or sufﬁ  cient on their own (EUROASPIRE II 
Study Group 2001). Large clinical outcome trials have shown 
that cardiovascular morbidity and mortality can be reduced 
signiﬁ  cantly by the use of antihypertensive agents (ALLHAT 
investigators 2002; Turnbull 2003; Julius et al 2004) and 
lipid-lowering drugs, particularly statins (Heart Protection 
Study Collaborative Group 2002; Sever et al 2003) in both 
secondary (Scandinavian Simvastin Survival Group 1994) 
and primary prevention (Shepherd et al 1995).
Further evidence has accumulated to guide how inten-
sively patients at risk should be treated. Targets for BP are 
based on meta-analyses from the major trials (Blood Pressure 
Lowering Treatment Trialists’ Collaboration 2003; Turnbull 
et al 2005) and especially the results of large outcomes trials 
(Hansson et al 1998). Targets for LDL-C were set initially 
on the basis of older landmark statin studies (Scandinavian 
Simvastin Survival Group 1994; Sever et al 2003); however 
there have been calls to further reduce these goals (Grundy 
et al 2004) on the basis of more recent trials, which indicate 
that risk of cardiovascular disease can be further lowered 
by treating to more aggressive targets (Cannon et al 2004; 
Nissen et al 2004). Furthermore, mortality improvements 
have been observed in patients with multiple risk factors, 
but only normal to mildly elevated cholesterol at baseline 
(mean total cholesterol  6.5 mmol/L in ASCOT) (Sever 
et al 2003). For lipid lowering, it is known from MRFIT that 
every 0.5 mmol/L increase in total cholesterol corresponds to 
an increase in CHD mortality risk of 12% and an increase in 
mortality risk of 17% when adjusted for regression dilution 
bias. Furthermore, the major lipid reduction trials have shown 
that every 1 mmol/L reduction in TC was associated with a 
23% reduction in CHD and 21% reduction in total vascular 
risk (Baigent et al 2005). There is also strong evidence from 
intervention trials that beneﬁ  t of this magnitude is achieved 
whichever method is used to reduce cholesterol levels.
Guidelines for management of cardiovascular risk factors 
rely on physicians and patients recognizing the need to 
reduce cardiovascular risk and accepting the huge evidence-
base supporting the recommended interventions. However, 
the observed suboptimal treatment patterns and failure to 
achieve guideline-recommended treatment goals (Figure 1) 
are compounded by patient non-concordance with prescribed 
therapies – up to 50% of patients choose to stop their medi-
cation of their own volition for a variety of reasons (Insull 
1997), and often within a few months of starting treatment. 
Clearly, adherence to treatment will inﬂ  uence whether ben-
eﬁ  ts are translated into reductions in morbidity and mortality Vascular Health and Risk Management 2006:2(4) 465–475
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Even though women have a higher frequency of chest pain/angina than men, the
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(Shepherd et al 1995; Flack et al 1996). Factors reported to 
inﬂ  uence adherence include patient education, cost, patients’ 
attitudes towards treatment, differences in dosing regimens, 
history of cardiovascular disease, numbers of concomitant 
medications and side effects (Schroeder et al 2004; Chapman 
et al 2005). There are reasons in addition to non-adherence, 
which may help to explain why treated patients do not attain 
target levels, for example, lack of response to a speciﬁ  c 
therapy.
Physician performance in delivering 
guideline recommendations for CVD risk
Despite the widely acknowledged severe burden of cardio-
vascular disease, previous studies conducted in a variety of 
locations and settings have demonstrated that many patients 
at risk remain unidentiﬁ  ed and or untreated. One survey 
conducted in Europe and Canada has indicated that up to 
60% of treatment-eligible patients are not receiving treat-
ment for their hypertension, ranging from 38% in Canada, 
to 59% in Germany (Wolf-Maier et al 2004). A similar 
pattern has been recorded for patients with coronary heart 
disease and elevated lipid levels in Europe (EUROASPIRE 
I and II Group).
The way physicians increment therapy also contributes 
to under-treatment: typically, physicians treat patients with 
additional cardiovascular risk factors by managing each risk 
factor separately, often sequentially rather than in parallel 
(Pearson et al 2000; Rosal et al 2004). This approach adds 
to pill burden and requires multiple physician visits to 
achieve appropriate drug titration for each risk factor. Even 
among those patients receiving adequate treatment for both 
conditions, few patients are at goal. This treatment gap could 
widen as target levels are reduced (Grundy et al 2004). 
There is also suboptimal management and little improve-
ment over time of other cardiovascular disease risk factors, 
such as smoking and obesity (Rosal et al 2004; Agarwal 
et al 2006).
Patient factors that inﬂ  uence patient 
concordance with therapy
In a retrospective cohort study of patients in a US managed-
care plan, it was found that adherence to concomitant 
antihypertensive and lipid-lowering therapy was poor, 
with only one in three patients adherent to both medica-
tions at 6-months (Wolf-Maier et al 2004). Pill count is 
an important issue, since patients are less likely to reﬁ  ll 
their antihypertensive and lipid-lowering prescriptions as 
their total number of prescriptions increases (Wolf-Maier 
et al 2004). Synchronization of antihypertensive and lipid-
lowering therapy initiation (ie, initiating both therapies 
simultaneously) also improves adherence in comparison 
with patients starting one therapy more than 30-days prior 
Figure 1 Rates of hypertension prevalence, treatment, and control in eight countries.
Hypertension Prevalence, Treatment and
Control: North America and Europe
1. Wolf-Maier K et al. JAMA.2003;289:2363-2369; 2. Wolf-Maier K et al. Hypertension. 2004;43:10-17.
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men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
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to the other (Agarwal et al 2006), and adherence decreases 
as the time between initiation of antihypertensive and lipid-
lowering therapies is prolonged (Wolf-Maier et al 2004). 
Increased cost of multiple prescriptions has been shown 
to have a large impact on adherence. For example, 25% of 
senior ( 65 years) Medicare beneﬁ  ciaries in a 2003 survey 
reported forgoing prescription medications in the past year 
because of cost (Safran et al 2005).
Physicians may therefore be able to signiﬁ  cantly improve 
medication adherence by initiating antihypertensive and 
lipid-lowering therapy concomitantly and by reducing pill 
burden and costs to the patient – goals that may be aided 
by single-pill therapy combining an antihypertensive with 
a lipid lowering agent. Patient adherence to medication has 
been shown to be signiﬁ  cantly greater with a single-pill regi-
men compared with a two-pill regimen for antihypertensive 
therapy alone (Julius et al 2004), and also when antihyperten-
sive and lipid-lowering therapies are initiated together versus 
sequentially (Wolf-Maier et al 2004; Dahlof et al 2005).
Rationale for amlodipine besylate/
atorvastatin calcium combination
With evidence showing that drug combinations improve 
patient compliance and persistence with therapy, this pro-
vides the rationale for the amlodipine besylate/atorvastatin 
calcium combination – a single-pill medication that treats 
both hypertension and dyslipidemia.
Amlodipine component
Amlodipine besylate is approved for the treatment of hyper-
tension and both vasospastic and chronic stable angina, alone 
or in combination with other agents. Amlodipine has been 
demonstrated to be well tolerated and effective at lowering 
BP in a wide variety of patients at risk of cardiovascular 
disease (ALLHAT Investigators 2002; Bisognano et al 2004; 
Julius et al 2004; Dahlof et al 2005). It has been shown to 
reduce cardiovascular events in both hypertensive patients 
(Dahlof et al 2005; Safran et al 2005; Agarawal et al 2006) 
and normotensive patients with coronary artery disease 
(Safran et al 2005).
The primary action of calcium channel blockers is to 
inhibit calcium (Ca2+) entry through voltage-gated trans-
membrane L-type channels, thus decreasing intracellular 
Ca2+ concentration and inducing smooth muscle relaxation. 
Amlodipine has been tested extensively in clinical trials and 
has been used for the treatment of hypertension since 1990 
in Europe and 1992 in the US.
Atorvastatin component
Atorvastatin calcium is a synthetic lipid-lowering agent, 
available in dosage strengths of 10, 20, 40, or 80 mg. 
Atorvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase, which catalyzes the 
conversion of HMG-CoA to mevalonate. This action occurs 
at an early and rate-limiting step in cholesterol biosynthesis 
and, consequently, is an important target for the develop-
ment of cholesterol-lowering agents (Jukema et al 2004). 
Inhibition of HMG-CoA reductase leads to upregulation of 
LDL-receptors in the liver, mediated by activation of sterol 
regulatory element-binding proteins and enhanced clear-
ance of LDL from the circulation. Because lipoproteins 
that inﬁ  ltrate the vessel wall initiate the development of 
atherosclerotic lesions, and oxidized LDL particles may 
trigger or enhance atherogenicity, HMG-CoA reductase 
inhibitors (statins) have an important role in therapy to 
prevent atherosclerosis.
Atorvastatin, a second-generation statin, was introduced 
in 1996 and gives LDL-C reductions of 41%–61% in hyper-
cholesterolemic patients. Individualization of drug dosage 
should be based on therapeutic response. Atorvastatin has 
been extensively tested in clinical trials and has shown 
impressive reductions in cardiovascular events (Grundy 
et al 2004). The efﬁ  cacy of atorvastatin monotherapy also 
has been demonstrated in diverse patient types analyzed in 
major clinical endpoint trials (Athyros et al 2002; Cannon 
et al 2004; Colhoun et al 2004).
In addition to the treatment of hypercholesterolemia, ator-
vastatin is indicated for reducing the risk of cardiovascular 
disease events in diabetic patients without clinically evident 
coronary heart disease, but with at least one additional cardio-
vascular risk factor. Furthermore, details of the CV beneﬁ  ts 
observed in hypertensive patients with 3 or more additional 
risk factors in ASCOT-LLA are included in the UK label, 
although an indication for the prevention of CV events in this 
group of patients is not mentioned speciﬁ  cally.
Amlodipine and atorvastatin have therefore been shown 
in major outcome studies to be safe and effective. There are 
no reported safety issues with the combined use of these two 
medications. Each is effective in the target population of the 
other, and neither component negatively impacts the efﬁ  cacy 
of the other. In terms of pharmacokinetics, both agents have 
long half-lives, allowing once-daily administration. Both 
agents can be dosed at any time of the day. Neither drug 
has any interaction with foods, or affects the other drug’s 
pharmacokinetic proﬁ  le.Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Single pill of amlodipine/atorvastatin
Simplifying drug regimens and reducing “pill burden” 
have been shown to enhance patient adherence. This 
could be particularly relevant for patients at high risk of 
cardiovascular disease who will often be prescribed com-
plex drug regimens to appropriately manage their multiple 
cardiovascular risk factors. The logic of combining multiple 
risk interventions for this multifactorial disease has been 
widely debated following the concept of the “polypill” for 
cardiovascular disease prevention (Law et al 2003; Wald 
and Law 2003).
Clinical evidence for amlodipine/
atorvastatin (Caduet) combination 
therapy
Pre-registration studies of Caduet were extensive, 
using Atorvastatin and Amlodipine pills separately 
but concurrently. Co-administration of amlodipine and 
atorvastatin has been demonstrated to be safe and effec-
tive for lowering both BP and LDL-C in patients with 
concomitant hypertension and dyslipidemia (Blank et al 
2005; Dorval et al 2005; Messerli et al 2006). The half-
lives of both agents facilitate once-daily dosing, and both 
can be administered at any time of day with or without 
food (Preston et al 2004). Neither drug has any adverse 
effects on the other’s efficacy or tolerability (Preston 
et al 2005a, b; Hobbs et al 2006). Bioequivalence has 
been demonstrated for both amlodipine and atorvastatin 
when fixed-dose combination tablets in strengths of 5/10 
or 10/80 mg amlodipine/atorvastatin were compared 
with commercially available amlodipine and atorvas-
tatin tablets coadministered in matching doses (Flack
et al 2003).
Following successful registration, amlodipine/atorvas-
tatin (Caduet) tablets are available for oral administration 
in 11 dose-strength combinations for use in the US. In some 
countries of the European Union two dose strengths 
are available (5 mg amlodipine/10 mg atorvastatin, and 
10 mg amlodipine/10 mg atorvastatin). Single-pill amlodip-
ine/atorvastatin is indicated in Europe for the prevention of 
cardiovascular events in hypertensive patients, with three 
concomitant cardiovascular risk factors, normal to mildly 
elevated cholesterol levels, and without clinically evident 
coronary heart disease where combined use of amlodipine 
and low dose atorvastatin is appropriate.
Since registration, several clinical trials have been con-
ducted to assess the efﬁ  cacy and safety of the combination 
therapy.
GEMINI (Wilson et al 1998)
GEMINI was the first Real World trial conducted to 
examine the use of amlodipine/atorvastatin (Caduet) single-
pill therapy for the concomitant treatment of hypertension 
and dyslipidemia (Wilson et al 1998). This 14-week, 
open-label, non-comparative, multicenter trial based in 
the US demonstrated the broad utility of the combina-
tion treatment in getting 1220 patients with uncontrolled 
hypertension and concurrent dyslipidemia to achieve both 
BP and LDL-C goals, based on JNC VI and NCEP ATP 
guidelines (Figure 2). At study end, more than half of the 
patients had reached both their BP and LDL-C therapeutic 
targets. Over 65% of patients reached their respective Joint 
National Committee on Prevention, Detection, Evaluation, 
and Treatment of High Blood Pressure VI (JNC VI) goal 
at study end, and 82% attained their National Cholesterol 
Education Program Adult Treatment Panel III (NCEP 
ATP III) goal. Figure 1 shows the percentages of patients 
reaching their BP, LDL-C or both therapeutic targets, based 
on baseline CVD risk category (Wilson et al 1998). Data 
were also presented regarding the performance of Caduet 
in patients who meet the IDF criteris for the metabolic 
syndrome (IDF).
The open-label GEMINI study also demonstrated that 
the amlodipine/atorvastatin single pill has a safety proﬁ  le in 
a real-world ofﬁ  ce setting consistent with its components, 
as previously documented in randomized, controlled clinical 
trials, including RESPOND and AVALON (Flack et al 2003; 
Hobbs et al 2006). In GEMINI, the most frequently reported 
adverse events (regardless of cause) were respiratory tract 
infections (11.9%), peripheral edema (8.8%), headache 
(5.4%) and myalgia (4.2%).These data demonstrated that 
co-administered amlodipine plus atorvastatin is well tolerated 
in patients with hypertension and additional risk factors, and 
that the adverse events observed are similar in nature, severity 
and frequency to those seen with amlodipine or atorvastatin 
administered alone.
The JEWEL Program (Hobbs et al 2006)
This program consisted of two 16-week, international, 
open-label, multicenter, titration-to-goal studies (JEWEL 
I and II) in 2219 patients with hypertension and dyslip-
idemia. The two studies differed based on country of 
enrollment (I with 1135 patients was based in the UK 
and Canada (Nichol et al 2006), and II with 1034 patients 
was based in 8 other major European countries) and 
primary endpoints in terms of treatment targets – these Vascular Health and Risk Management 2006:2(4) 465–475
© 2006 Dove Medical Press Limited. All rights reserved
465
REVIEW
Leila Fernandes Araujo
Alexandre de Matos Soeiro
Juliano Lara Fernandes
Antônio Eduardo Pesaro
Carlos V Serrano Jr
Heart Institute (InCor), University
of São Paulo, School of Medicine,
Brazil
Correspondence: Carlos V Serrano Jr
Coronary Care Unit, Av. Dr. Enéas
Carvalho Aguiar, 44 – sala 12 – bloco 2,
São Paulo - SP - 05403-900, Brazil
Tel +55 11 3069 5058
Fax +55 11 3088 3809
Email carlos.serrano@incor.usp.br
Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
Keywords: coronary artery disease, women, risk factors, prevention, diagnosis, treatment.
Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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were determined by what the prevailing targets were by 
country (Canada, UK [audit targets], and European Society 
of Cardiology [Conroy et al 2003] guidelines) as seen in 
Figure 4. Patients were initiated at a dose of amlodipine 
besylate 5 mg/atorvastatin calcium 10 mg, and the dose 
was uptitrated as necessary.
Different combinations of doses of amlodipine 
besylate/atorvastatin calcium were used in the study, and 
the majority of patients achieved their BP and LDL-C 
targets (varied between UK, Canada and Europe) with the 
5/10 and 10/10 combination doses. Figure 2 illustrates the 
percentages of patients attaining the BP and/or LDL-C 
goals.
In terms of safety proﬁ  le, peripheral edema and myalgia 
occurred in a small proportion of patients, with myalgia 
occurring at a lower than expected rate.
GEMINI AALA
With a study design similar to that of GEMINI conducted 
in the United States, this trial included 1649 patients with 
*CHD risk equivalent=diabetes or other clinical forms of atherosclerotic disease.
CADUET Trials: Patient Populations
Groups I, II, and III (except JEWEL)
<100 mg/dL <130 mg/dL <160 mg/dL
LDL-C Goals
(NCEP ATP III)
SBP <130 mm Hg
and
DBP <85 mm Hg
[DBP <80 mm Hg]
SBP <140 mm Hg
and
DBP <90 mm Hg
SBP <140 mm Hg
and
DBP <90 mm Hg
BP Goals
(JNC VI)
[JNC VII]
JEWEL I&II –
Varied Goals
CHD or CHD risk 
equivalent*
At least one 
additional
CVD risk factor
No additional
CV risk factors
Additional CVD Risk 
Factors
101-250 mg/dL 131-250 mg/dL 161-250 mg/dL
Fasting
LDL-C
130-159 mm Hg
and/or
85-99 mm Hg
140-179 mm Hg
and/or
90-109 mm Hg
140-179 mm Hg
and/or
90-109 mm Hg
Blood Pressure
Group III Group II Group I
Figure 2 Blood pressure and lipid targets for the GEMINI and CAPABLE trials, based on JNC VI blood pressure and NCEP ATP lipid recommendations.
Figure 3 Percentage of GEMINI patients at blood pressure, lipid, or combined targets by cardiovascular disease risk category (NCEP ATP I to III risk categories) at baseline.
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•  CV Risk Group I – Hypertension 
and dyslipidemia
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and dyslipidemia and presence of 
at least one other CVD risk fac-
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  55 years, premature CHD in ﬁ  rst-
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
Coronary artery disease in women: a review
on prevention, pathophysiology, diagnosis, and
treatment
A
u
t
h
o
r
 
c
o
p
y
 
o
n
l
y
Vascular Health and Risk Management 2007:3(5) 717
Single pill of amlodipine/atorvastatin
diverse ethnic backgrounds across 27 countries in Asia, 
Africa, the Middle East and Latin America. Fifty-two percent 
of the patients in GEMINI AALA were of Asian and 15% of 
Hispanic ethnicity. Preliminary results show that an overall of 
55.2% of patients achieved both JNC VI BP and NCEP ATP 
III LDL-C therapeutic goals after 14 weeks of treatment. A 
post-hoc analysis conducted among a subgroup of patients 
in Eastern Asian countries (excluding Australia, India, and 
Pakistan) further shows that the mean Framingham 10-year 
CHD risk score was reduced by 51.6% with Caduet single-
pill treatment.
The treatment was generally well tolerated by patients. 
The majority of peripheral edema cases was mild to moder-
ate in severity, and resulted in only 4 discontinuations. The 
incidence of myalgia was lower than expected, and none 
resulted in discontinuations.
CAPABLE
The CAPABLE study conducted in the US, investigated the 
efﬁ  cacy, safety and clinical utility of single-pill amlodipine/
atorvastatin therapy among 499 African-American patients) 
with concomitant hypertension and dyslipidemia (under-
researched group (Flack et al 2006a). Research to study 
therapies for the reduction of cardiovascular risk in the African-
American population is particularly important as hypertension 
is more common among African-Americans than other US 
ethnic groups (Flack et al 2003). The design of the CAPABLE 
study was similar to that of the GEMINI study, but enrolled 
500 African-American men and women and analyzed BP and 
LDL-C goal attainment over 20 weeks rather than all ethnic 
groups with 14 weeks of follow up. Overall, at the end of 
CAPABLE 48.3% of patients reached both their blood pressure 
and LDL-C goals (compared with 0.8% at baseline) indicating 
the utility of amlodipine/atorvastatin to lower BP and lipid 
levels in this ethnic minority population, which is at a high risk 
of CVD events. A substudy of CAPABLE also demonstrated 
that amlodipine/atorvastatin improves 24 hour ambulatory BP 
(Flack et al 2006b).
Figure 4 Blood pressure and lipid targets for the JEWEL I and II studies, based on country speciﬁ  c recommendations.
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Figure 5 Proportions of patients meeting either blood pressure or lipid targets 
and both in JEWEL I and II studies after 16 weeks of amlodipine/atorvastatin 
(Caduet) therapy in 2219 patients.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Real-life prescribing data
The Caduet Concordance Research Program and Education 
(CARPE)-PBM Concordance Study (Nichol et al 2006) 
utilized claims data from a large US database, to assess 
differences in concordance between single-pill amlo-
dipine/atorvastatin therapy in comparison with separate 
antihypertensive and lipid-lowering therapies. The study 
showed that the probability of achieving concordance with 
single-pill amlodipine/atorvastatin was almost twice that 
for amlodipine and atorvastatin taken separately. Compared 
with patients taking another antihypertensive and another 
statin separately, patients receiving amlodipine/atorvas-
tatin were almost three times as likely to be adherent to 
both classes of medication (Nichol et al 2006).
Conclusion
CVD is the most important cause of death and disability 
in the world. The most important treatable risk factors are 
hypertension and dyslipidemia. Despite effective therapies, 
patient concordance with multiple therapies is problematic. 
The amlodipine/atorvastatin single pill (Caduet) is the ﬁ  rst 
combination therapy treating two risk factors simultaneously, 
targeting patients with co-existing hypertension and dyslipid-
emia. It has been shown to improve rates of goal attainment 
and to be as well tolerated as the parent compounds given 
individually.
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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
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